Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation-Reference-Cited by-同舟云学术

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation

Published:2019-10-06 Issue:4 Volume:188 Page:540-549
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kaloyannidis Panayotis¹,Hertzberg Mark²,Webb Kate³,Zomas Athanasios⁴,Schrover Rudolf⁵,Hurst Michael⁶,Jacob Ian⁶^ORCID,Nikoglou Thalia⁴,Connors Joseph M.⁷^ORCID

Affiliation:

1. King Fahad Specialist Hospital Dammam Saudi Arabia

2. Prince of Wales Hospital, and University of NSW Randwick NSW Australia

3. Takeda Pharmaceuticals Sydney NSW Australia

4. Takeda Europe & Canada Business Unit (EUCAN) Zurich Switzerland

5. SYNEVi Pty Limited Chatswood NSW Australia

6. Health Economics and Outcomes Research Ltd Cardiff UK

7. BC Cancer Centre for Lymphoid Cancer and the University of British Columbia Vancouver BC Canada

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16201

Reference29 articles.

1. Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study

2. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

3. Australian Government Department of Health(2016)Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory. Committee Available https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf.

4. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study

5. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil;Cancers;2024-09-03

2. In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869;Cells;2023-11-29

3. Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary;Annals of Hematology;2023-07-10

4. Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness;Contemporary Clinical Trials Communications;2023-06

5. Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy;Critical Reviews in Oncology/Hematology;2023-02